RoboCT (程天科技), an exoskeleton builder with a focus on rehabilitation, has received a license from China’s medical authorities, marking a crucial step for the firm to accelerate its market expansion.
The Hangzhou-headquartered firm announced recently that its KidGo rehab exoskeleton series, aimed at assisting children with mobility impairment in lower limbs, had secured a certificate from the nation’s National Medical Products Administration (NMPA).
The exoskeleton targets children with cerebral palsy, brain damage, spinal cord injury, myasthenia gravis — meaning a lack of muscle power — and other central nervous system diorders.
Available in individual and rehab versions, the KidGo robotic suit can be worn to provide active and passive therapeutical sessions for young victims of mobility impairment like paralysis or other physical handicaps.
The exoskeleton guides the user to undergo physiotherapy through a gamified training mode, filling the process with fun and thus motivating the user to challenge his or her limits during treatment at the clinical and post-clinical stages.
The individual edition of KidGo is a simplified version of the professional variant, meant to be used in hospitals and rehab centers.
In a home scenario, its intuitive design and working mechanism feature adequate ease of use for children to feel comfortable with.
One of a handful of domestic startups looking to apply its technologies in the rehab space, RoboCT has a product line consisting of seven lower extremity exoskeletons and multiple accessories.
cnrobopedia reported in early October that RoboCT had just closed a new funding round for an undisclosed amount to advance its R&D work and talent recruitment.
